N/A N=3 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
Stroke, Ischemic · Inflammatory Response · Stroke, Acute
Primary: Changes in TSPO Radiotracer Uptake Infarct Area — 1.54 g/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=240 A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes
Healthy Volunteers
Primary: Concentration of Carboxyhemoglobin in Blood — -59.6; -62.7; -46.4; -62.7 % change from baseline
Phase 3 N=438 A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
COVID-19 Pneumonia
Primary: Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4) — 56.5; 49.3; 2.0; 5.6 Percentage of Participants — p=0.3600
Phase 1 N=40 A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity
Hallux Valgus Deformity
Primary: Surgical Site Assessment — 0; 0; 0; 0 Number of skin reactions
Phase 1 N=40 Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
Healthy Adults
Primary: Incidence of Adverse Events (AEs) [Safety and Tolerability] — 2; 4; 3; 6 Participants
N/A N=47 Esophageal Deviation in Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge…
N/A N=52 Telephone Coaching of Family Members of Veterans With Substance Abuse Problems
Substance Abuse
Primary: Number of Veteran's Engaged in Mental Health Care — 7; 5 Participants — p=>.05
Phase 2 N=24 Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Non-metastatic Renal Cell Carcinoma
Primary: Number of Patients With a Change in Mayo Classification — 6; 15 Participants
Phase 2 N=210 Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Anthrax
Primary: Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35 — 0.9764; 0.9706 Ratio
Phase 2 N=572 Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Lyme Borreliosis
Primary: GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6 — 74.3; 101.9; 115.8; 21.7 U/mL
Phase 3 N=155 KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
ADHD
Primary: Change From Baseline in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores — -4.87; 0.536 score on a scale — p=<0.001
Phase 4 N=23 SGLT2 Inhibition in Combination With Diuretics in Heart Failure
Heart Failure · Type 2 Diabetes Mellitus
Primary: The Effect of Empagliflozin Versus Placebo on the Change in Urine Output. — 545; -113 mL — p== 0.005
Phase 3 N=1,483 Pre-exposure Prophylaxis for SARS-Coronavirus-2
COVID-19 · Corona Virus Infection · ARDS
Primary: COVID-19-free Survival — 464; 468; 454 Participants
Phase 2 N=129 AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
Coronary Artery Disease
Primary: Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 — 0.04; 0.09; 1.09 Ratio — p=<0.001
Phase 4 N=102 A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Pouchitis
Primary: Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14 — 9.8; 31.4 percentage of participants — p=0.013